Background
Dementia with Lewy bodies (DLB) is emerging as a common cause of degenerative dementia. Some preliminary evidence exists that the pattern of cognitive impairment in DLB is different from that in Alzheimer disease (AD).
Objective
To delineate features of cognitive impairment of DLB on standardized neuropsychological tests.
Methods
We performed neuropsychological assessments of 26 patients with probable DLB (based on criteria of the consortium on DLB international workshop) and of 52 patients with probable AD (based on criteria of the National Institute of Neurological and Communicative Disorders and Stroke [now the National Institute of Neurological Disorders and Stroke])–Alzheimer's Disease and Related Disorders Association) who were matched to the patients with DLB 2:1 by age, sex, education, and Mini-Mental State Examination score.
Results
Compared with the group with probable AD, the group with probable DLB scored significantly lower on the picture arrangement, block design, object assembly, and digit symbol substitution subtests of the Wechsler Adult Intelligence Scale–Revised and on the Raven Colored Progressive Matrices test and significantly higher on the Mini-Mental State Examination locational orientation subtest and the Alzheimer's Disease Assessment Scale word recall subtest. A discriminant analysis revealed that the word recall score on the Alzheimer's Disease Assessment Scale and the block design score on the Wechsler Adult Intelligence Scale–Revised were the best discriminant factors.
Conclusions
The disproportionately severe visuoperceptual, visuoconstructive, and visuospatial dysfunction and the disproportionately mild memory impairment in DLB compared with AD, which likely reflect the distribution of the pathologic changes in DLB, can help to differentiate DLB from AD.
A DEGENERATIVE dementia characterized by the presence of Lewy bodies in cortical and brainstem structures has been variously referred to as "diffuse Lewy body disease,"1,2 "senile dementia of the Lewy body type,"3 or "the Lewy body variant of Alzheimer disease [AD]."4 In 1996, an international workshop5 recommended "dementia with Lewy bodies [DLB]." This disorder is increasingly being recognized as a common cause of dementia in elderly people and is probably the second most common type after AD in postmortem studies.6 Clinically, DLB is characterized by progressive dementia and often occurs with a fluctuating course, extrapyramidal signs, hallucinations, and increased sensitivity to neuroleptic drugs.3
When the initial presentation of DLB is impaired cognition, DLB is difficult to differentiate from AD at the onset of the illness.4 Histopathological features of AD, usually coexisting with Lewy bodies probably contribute to the symptoms associated with DLB, likely making the clinical differentiation between DLB and AD difficult. Retrospective studies of a limited number of patients whose diagnoses have been pathologically verified have indicated that the pattern of cognitive impairment in DLB is different from that in AD.4,7-9 Preliminary studies of patients clinically diagnosed as having DLB also have suggested a possible usefulness of cognitive assessment in differentiating the 2 diseases.10-12 However, studies based on a large number of patients and comprehensive neuropsychological assessments are lacking. In the present study, to delineate distinctive features of cognitive impairment between DLB and AD, we assessed the performance of patients with probable DLB and those with probable AD on standardized neuropsychological tests.
Patients with probable DLB or AD were recruited from those who were admitted from July 1, 1993, to April 30, 1997, to the infirmary of the Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan, a research-oriented hospital for dementia, for investigation. All patients were examined comprehensively by both neurologists and psychiatrists and were given standard neuropsychological examinations, routine laboratory tests, electroencephalography, cranial magnetic resonance imaging, and nuclear neuroimaging studies. Staff physicians closely monitored the fluctuation of cognitive functions during 1-month hospital stays in terms of Mini-Mental State Examination (MMSE) performance, activities of daily living, and episodic confusion. The clinical and investigative data that were collected prospectively in a standardized manner were entered into the institute's dementia registry. The whole procedure followed the Clinical Study Guidelines of the Ethics Committee of the institute and was approved by the Internal Review Board in 1993. Informed written consent was obtained from the subjects and their relatives.
Patients With Probable DLB
The group with probable DLB comprised 26 patients. The inclusion criteria for DLB were the clinical criteria of the consortium on DLB international workshop,5 the absence of any complication of other neurological diseases, and the absence of any evidence of focal brain lesions on magnetic resonance imaging. The consortium criteria for DLB include 3 core features—fluctuating cognitive functions, recurrent visual hallucinations, and spontaneous parkinsonism—and 2 of them are necessary for a diagnosis of probable DLB. The mean±SD age was 73.6±5.1 years for the 16 women and 10 men. The mean±SD educational attainment was 8.8±2.0 years, and the mean±SD score (the best performance in repeated measures) of the MMSE13 was 16.4±4.0. Nine patients with probable DLB had fluctuating cognition and visual hallucinations, 7 had fluctuating cognition and parkinsonism, 4 had visual hallucinations and parkinsonism, and 6 had all 3 features. These 4 subgroups of patients with probable DLB did not differ significantly in age, sex, years of education, MMSE score, or duration of illness (Table 1).
Patients With Probable AD
The group with probable AD comprised 52 patients. Patients were sampled from the same cohort as those with probable DLB and were matched to the patients with probable DLB 2:1 on the basis of age, sex, years of education, and MMSE score. The inclusion criteria for AD were those of the National Institute of Neurological and Communicative Disorders and Stroke (now the National Institute of Neurological Disorders and Stroke)–Alzheimer's Disease and Related Disorders Association for probable AD,14 the absence of any complication of other neurologic diseases, and the absence of any evidence of focal brain lesions on magnetic resonance imaging. Those who fulfilled the criteria for possible DLB of the consortium on DLB international workshop5 (the presence of only 1 of the triad) were not included. The mean±SD age was 73.7±5.1 years for the 32 women and 20 men. The mean±SD educational attainment was 9.2±2.1 years, and the mean±SD MMSE score was 16.5±4.0.
Duration and Global Severity of Dementia
The "onset of dementia" was defined as the moment of the nearest caregiver's awareness of the patient's cognitive abnormality. The "duration of dementia" was the interval from the onset to the assessment and was expressed in months. Global severity of dementia was assessed with the Clinical Dementia Rating Scale.15 In this scale, functional severity of dementia is graded into 5 classes as 0 (none), 0.5 (very mild), 1 (mild), 2 (moderate), and 3 (severe).
Neuropsychological Assessments
Cognitive functions were assessed with standard neuropsychological tests, including Alzheimer's Disease Assessment Scale-cognitive part (ADAS),16 Raven Colored Progressive Matrices,17 and the Wechsler Adult Intelligence Scale–Revised (WAIS-R).18 The assessments were performed while the subject was free from neuroleptic and neurotropic agents and not in a state of confusion or with active hallucinations.
Orientation was assessed by using the temporal and locational orientation subtests of the MMSE.13 The former includes 5 questions about time (month, date, year, season, and time of day), and the latter includes 5 questions about location (prefecture, city, name of hospital, floor, and number of rooms in the hospital). Verbal memory was assessed by using the ADAS recall and recognition subtests.19 The ADAS word recall subtest is equivalent to a verbal learning test, in which the retention of a list of 10 written words was measured by free immediate recall after each of 3 learning trials. The score is expressed as the mean number of words recalled in 3 trials. In the ADAS word recognition subtest, the subject was asked to read aloud 12 written high-imagery words and then to select the target words among 24 words randomly mixed with 12 irrelevant words. The score is expressed as the mean number of correct responses on 3 repeated trials. The ADAS construction subtest score (number of correct responses) was also analyzed as an untimed drawing task. The ADAS total score was analyzed as another index of severity of dementia by overall cognitive impairment.
The performance on each subtest of the WAIS-R—information, digit span, vocabulary, arithmetic, comprehension, similarities, picture completion, picture arrangement, block design, object assembly, and digit symbol substitution—was separately considered, and the verbal and performance IQs were calculated. The score of each subtest was age-corrected according to the manual. The Raven Colored Progressive Matrices measures visuospatial reasoning. The score was the number correctly identified.
Statistical analyses were carried out with commercially available software (SAS Version 6.10, SAS Institute, Inc, Cary, NC). Group differences were analyzed by using the 2-tailed Student t test, the 2-tailed Mann-Whitney U test, or an analysis of variance as appropriate, with significance set at P<.05. No correction for multiple comparisons was carried out because of the exploratory nature of the study. To identify the neuropsychological tests most likely to distinguish probable DLB from probable AD, a stepwise discriminant-function analysis was used, with significance set at P<.01. Data are expressed as means±SDs.
The duration of dementing illness was significantly shorter in the group with probable DLB than in the group with probable AD (t76=2.83; P=.006); the duration after the onset of cognitive impairments was 26.6±23.9 months in the group with probable DLB and 42.1±24.5 months in the group with probable AD. There was no significant difference in the ADAS scores between the 2 groups (t76=0.62; P=.54); the ADAS total score was 26.4±9.4 in the group with probable DLB and 27.9±11.1 in the group with probable AD. The global severity of dementia as demonstrated by the Clinical Dementia Rating Scale was comparable between the 2 groups (U76=636; P=.68); the Clinical Dementia Rating Scale scores of 0.5, 1, 2, and 3 were obtained by 0, 16, 7, and 3 patients, respectively, in the group with probable DLB and by 6, 24, 19, and 3 patients, respectively, in the group with probable AD.
There was no significant difference in neuropsychological test scores among subgroups of probable DLB defined by the presence of a cluster of key symptoms (Table 1). The results of each neuropsychological assessment in the groups with probable DLB and AD are presented in Table 2. The MMSE locational orientation score and the ADAS word recall score were significantly better in the group with probable DLB than in that with probable AD, whereas the ADAS construction score; WAIS-R picture arrangement, block design, object assembly, and digit symbol substitution subscale scores; and the Raven Colored Progressive Matrices score were significantly worse in the group with probable DLB than in the group with probable AD. As a result, the performance IQ was lower in the group with probable DLB than in the group with probable AD (62.5±9.1 vs 72.0±13.0; P<.001). No differences were found between the groups in the MMSE temporal orientation score or the ADAS word recognition score. Furthermore, there were no differences in the WAIS-R information, digit span, vocabulary, arithmetic, comprehension, similarities, or picture completion scores or in the verbal IQ (73.0±9.2 vs 75.6±9.4; P=.25).
Those variables that were found to be significantly different between the 2 groups were entered into a stepwise discriminant procedure. Two variables retained significant F values: the WAIS-R block design (partial r2=0.22, F1,75=21.53; P<.001) and the ADAS word recall (partial r2=0.12, F1,75=10.59; P=.002). The discriminant analysis was performed as follows: classification score for DLB=1.858×word recall+0.150×block design−4.710; and the classification score for AD= 1.188×word recall+0.644×block design−3.900. This model correctly predicted 53.8% cases of probable DLB and 88.5% cases of probable AD. Figure 1 illustrates the relation between the ADAS word recall and WAIS-R block design scores for probable DLB and AD.
In the present study, the patients with probable DLB and those with probable AD were comparable in the global severity of dementia and the global assessment of cognitive impairment. Nevertheless, the patients with probable DLB had a significantly shorter duration of illness; scored better on the verbal memory subtest of the ADAS; and performed worse on several tests of visuoperceptual, visuoconstructive, and visuospatial functions than the patients with probable AD. Psychomotor slowing accompanied by parkinsonism is unlikely to explain the low performance in visuoperceptual, visuoconstructive, and visuospatial tests in the patients with probable DLB because they performed worse even on the untimed measures, such as the ADAS construction subtest and the Raven Colored Progressive Matrices. No significant difference was noted among the subgroups of probable DLB with each combination of key symptoms, although this is inconclusive because of the small sample size of each subgroup. A discriminant analysis revealed that the ADAS word recall and WAIS-R block design scores were the best discriminant factors. The preferentially affected domains of cognitive function may differ between the 2 diseases.
These findings are consistent with the previous retrospective studies of a limited number of patients with proven disease.4,8,9 Comparing neuropsychological test results among patients with the pathologically proven Lewy body variant of AD, diffuse Lewy body disease, and AD, Galasko et al7 demonstrated that patients with the Lewy body variant of AD had significantly greater impairment on tests of visuospatial and visuoconstructive abilities. Hansen et al,4 comparing neuropsychological performance of 9 patients with the Lewy body variant of AD (Lewy body with concomitant AD) and 9 patients with definite AD matched for age, years of education, and overall severity of dementia, suggested that patients with the Lewy body variant displayed disproportionately severe deficits in attention, fluency, and visuospatial processing. In the study by McKeith et al8 where 21 patients with pathologically verified senile dementia of the Lewy body type and 37 patients with definite AD were examined, performance on the recall subtest of the Blessed Mental Test was better in the patients with senile dementia of the Lewy body type than in the patients with AD. Salmon et al,9 comparing the neuropsychological deficits of 5 patients with neuropathologically confirmed diffuse Lewy body disease with those of 5 patients with neuropathologically confirmed pure AD matched by dementia severity, found a poor visuoconstructive function and relatively preserved memory function in patients with diffuse Lewy body disease.
Poor visuospatial and relatively good memory performances on the Cambridge Cognitive Examination in patients with DLB have been demonstrated also in a prospective study, where 17 patients with probable DLB (satisfying the 1992 McKeith clinical criteria8 for senile dementia of Lewy body type) were compared with 17 patients with probable AD with comparable MMSE and global Cambridge Cognitive Examination scores.12 Furthermore, Gnanalingham et al,11 based on a study of 25 patients with probable AD and 16 patients with DLB (satisfying the 1992 McKeith criteria8 for senile dementia of Lewy body type and the 1989 Byrne clinical criteria1 for diffuse Lewy body disease), pointed out the usefulness of the clock-face test, which assesses executive and visuospatial functioning, in differentiating DLB from AD. Patients with AD do well on the "copy" part of the test despite doing poorly on the "draw" part, whereas patients with DLB do equally poorly on both parts of the test. Although it has been claimed that the specificity of this test is not as high as originally reported,20 the findings of Gnanalingham et al10,11 suggested that visuoconstructive ability is more impaired in DLB than in AD.
The distinctive features of neuropsychological impairment between the 2 diseases probably represent the different distributions of pathological changes. The visuoperceptual, visuoconstructive, and visuospatial dysfunction in probable DLB can be attributed to accentuated damage in the occipital and parietotemporal lobes. Albin et al21 demonstrated that regional glucose metabolism was decreased in the occipital association cortex and primary visual area in 6 patients with autopsy-proven DLB. In a recent study,22 using fludeoxyglucose F 18 and positron emission tomography, the glucose metabolic rate in the temporoparieto-occipital association cortices was significantly lower in patients with probable DLB (n=19) than in controls with probable AD matched by age, sex, disease duration, and MMSE scores. Occipital glucose hypometabolism has been reported in patients with Parkinson disease and dementia.23-25 The activity of a cholinergic enzyme—choline acetyltransferase—is reportedly lower in the temporoparietal and occipital neocortex in DLB compared with AD.26,27 The neurodegenerative processes in the basal nucleus of Meynert16 may preferentially involve the cholinergic neurons projecting to the occipital lobe, resulting in occipital dysfunction. The visuoperceptual, visuoconstructive, and visuospatial dysfunction in DLB can be attributed to the occipital cholinergic deficits.
On the other hand, the relatively preserved memory function in probable DLB is likely attributable to less involvement of the memory system, including the medial temporal lobe in DLB compared with AD. Our positron emission tomographic study also demonstrated that the medial temporal and cingulate glucose metabolism was significantly higher in patients with probable DLB than in patients with probable AD. Although in DLB, cortical Lewy bodies preferentially appear in the limbic structures,3,4 the density of limbic neurofibrillary tangles is lower in DLB than in AD,16,28 suggesting that dysfunction of the limbic system is milder in DLB than in AD. Lippa et al,29 comparing the hippocampal areas in specimens from patients with pure Lewy body disease, with Lewy bodies and histopathological features of AD, and with definite AD, found that hippocampal atrophy was less severe in pure Lewy body disease than in AD.
The visuoperceptual, visuoconstructive, and visuospatial dysfunctions are disproportionately severe and the verbal memory function is disproportionately mild in patients with probable DLB compared with those with probable AD. These features, which are compatible with neuropathological and neuroimaging findings in DLB, likely reflect the distribution of the pathologic changes in DLB. Neuropsychological assessments may help in differentiating DLB from AD.
Accepted for publication March 31, 1998.
Reprints: Etsuro Mori, MD, Department of Clinical Neurosciences, Hyogo Institute for Aging Brain and Cognitive Disorders, 520 Saisho-Ko, Himeji 670, Japan (e-mail: mori@hiabcd.go.jp).
1.Byrne
EJLennox
GLowe
JGodwin-Austen
RB Diffuse Lewy body disease: clinical features in 15 cases.
J Neurol Neurosurg Psychiatry. 1989;52709- 717
Google ScholarCrossref 3.Perry
RHIrving
DBlessed
GFairbairn
APerry
EK Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly.
J Neurol Sci. 1990;95119- 139
Google ScholarCrossref 4.Hansen
LSalmon
DGalasko
D
et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.
Neurology. 1990;401- 8
Google ScholarCrossref 5.McKeith
IGGalasko
DKosaka
K
et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology. 1996;471113- 1124
Google ScholarCrossref 6.McKeith
IGGalasko
DWilcock
GKByrne
EJ Lewy body dementia: diagnosis and treatment.
Br J Psychiatry. 1995;167709- 717
Google ScholarCrossref 7.Galasko
DKatzman
RSalmon
DPHansen
L Clinical and neuropathological findings in Lewy body dementias.
Brain Cogn. 1996;31166- 175
Google ScholarCrossref 8.McKeith
IGPerry
RHFairbairn
AFJabeen
SPerry
EK Operational criteria for senile dementia of Lewy body type (SDLT).
Psychol Med. 1992;22911- 922
Google ScholarCrossref 9.Salmon
DPGalasko
DHansen
L
et al. Neuropsychological deficits associated with diffuse Lewy body disease.
Brain Cogn. 1996;31148- 165
Google ScholarCrossref 10.Gnanalingham
KKByrne
EJThornton
A Clock-face drawing to differentiate Lewy body and Alzheimer type dementia syndrome.
Lancet. 1996;347696- 697
Google ScholarCrossref 11.Gnanalingham
KKByrne
EJThornton
ASambrook
MABannister
P Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's disease and Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997;62243- 252
Google ScholarCrossref 12.Walker
ZAllen
RLShergill
SKatona
CL Neuropsychological performance in Lewy body dementia and Alzheimer's disease.
Br J Psychiatry. 1997;170156- 158
Google ScholarCrossref 13.Folstein
MFFolstein
SEMcHugh
PR "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res. 1975;12189- 198
Google ScholarCrossref 14.McKhann
GDrachman
DFolstein
MKatzman
RPrice
DStadlan
EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
Neurology. 1984;34939- 944
Google ScholarCrossref 15.Hughes
CPBerg
LDanziger
WLCoben
LAMartin
RL A new clinical scale for the staging of dementia.
Br J Psychiatry. 1982;140566- 572
Google ScholarCrossref 16.Förstl
HBurns
ALuthert
PCairns
NLevy
R The Lewy-body variant of Alzheimer's disease: clinical and pathological findings.
Br J Psychiatry. 1993;162385- 392
Google ScholarCrossref 17.Raven
JC RCPM: Guide to Using the Colored Progressive Matrices. New York, NY Psychological Corp1965;
18.Wechsler
DA Manual for the Wechsler Adult Intelligence Scale–Revised. New York, NY Psychological Corp1981;
19.Mohs
RCRosen
WGDavis
KL The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy.
Psychopharmacol Bull. 1983;19448- 450
Google Scholar 20.Swanwick
GRCoen
RFMaguire
CPCoakley
DLawlor
BA Clock-face drawing to differentiate dementia syndrome [letter].
Lancet. 1996;3471115
Google ScholarCrossref 21.Albin
RLMinoshima
SD'Amato
CJFrey
KAKuhl
DASima
AAF Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.
Neurology. 1996;47462- 466
Google ScholarCrossref 22.Imamura
TIshii
KSasaki
M
et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography.
Neurosci Lett. 1997;23549- 52
Google ScholarCrossref 23.Peppard
RFMartin
WRCarr
GD
et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia.
Arch Neurol. 1992;491262- 1268
Google ScholarCrossref 24.Turjanski
NBrooks
DJ Positron emission tomography findings in Parkinson's disease and Lewy body disease. Perry
RHMcKeith
IGPerry
EKeds
Dementia With Lewy Bodies. Cambridge, UK Cambridge University Press1996;145- 152
Google Scholar 25.Vander Borght
TMinoshima
SGiordani
B
et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity.
J Nucl Med. 1997;38797- 802
Google Scholar 26.Langlaris
PJThal
LHansen
LGalasko
DAlford
MMasliah
E Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with or without Lewy bodies.
Neurology. 1993;431927- 1934
Google ScholarCrossref 27.Perry
EKHaroutunian
VDavis
KL
et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
Neuroreport. 1994;5747- 749
Google ScholarCrossref 28.Lippa
CFSmith
TWSwearer
JM Alzheimer's disease and Lewy body disease: a comparative clinicopathological study.
Ann Neurol. 1994;3581- 88
Google ScholarCrossref 29.Lippa
CFJohnson
RSmith
TW Medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease.
Ann Neurol. 1998;43102- 106
Google ScholarCrossref